Cargando…

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

BACKGROUND: Oncology therapy is becoming increasingly more expensive and challenging the affordability and sustainability of drug programmes around the world. When new drugs are evaluated, health technology assessment organisations rely on clinical trials to inform funding decisions. However, clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Kelvin, Nam, Seungree, Evans, Bill, de Oliveira, Claire, Chambers, Alexandra, Gavura, Scott, Hoch, Jeffrey, Mercer, Rebecca E, Dai, Wei Fang, Beca, Jaclyn, Tadrous, Mina, Isaranuwatchai, Wanrudee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955501/ https://www.ncbi.nlm.nih.gov/pubmed/31915169 http://dx.doi.org/10.1136/bmjopen-2019-032884

Ejemplares similares

Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration
por: Parmar, Ambica, et al.
Publicado: (2023)

Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned
por: Evans, William K., et al.
Publicado: (2022)

Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group
por: Dai, Wei Fang, et al.
Publicado: (2021)

Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group
por: Dai, Wei Fang, et al.
Publicado: (2022)

Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise
por: Dai, Wei Fang, et al.
Publicado: (2021)

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
por: Arciero, Vanessa, et al.
Publicado: (2022)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
por: Pataky, Reka E., et al.
Publicado: (2021)

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
por: Dai, Wei Fang, et al.
Publicado: (2020)

Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle
por: Tadrous, Mina, et al.
Publicado: (2020)

Real-world Evidence of the Herb-drug Interactions
por: Pan, Hsueh-Yi, et al.
Publicado: (2022)

What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward
por: Kc, Sarin, et al.
Publicado: (2023)

Integration of real-world evidence from different data sources in health technology assessment
por: Graili, Pooyeh, et al.
Publicado: (2023)

Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
por: Chan, Kelvin K. W., et al.
Publicado: (2019)

Real-world evidence in antiretroviral therapy: drug safety data
por: Silva, Ana-Marta, et al.
Publicado: (2020)

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
por: Khor, Sara, et al.
Publicado: (2014)

Real-World Evidence for Equality
por: Johnson, C. Erwin, et al.
Publicado: (2021)

Editorial: Real-world data and real-world evidence in hematologic malignancies
por: Malagola, Michele, et al.
Publicado: (2023)

Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario
por: Naipaul, Rohini D., et al.
Publicado: (2021)

Informing real-world practice with real-world evidence: the value of PRECIS-2
por: Neta, Gila, et al.
Publicado: (2018)

Proceed with Caution When Using Real World Data and Real World Evidence
por: Kim, Hun-Sung, et al.
Publicado: (2019)

4505 Implementation of Real-World Data and Real-World Evidence in Clinical Studies
por: Pham, Jessica, et al.
Publicado: (2020)

Drugs: Real World Outcomes
por: Peters, Dene C., et al.
Publicado: (2014)

Bisphosphonate Drug Holidays: Evidence From Clinical Trials and Real‐World Studies
por: Wang, Mawson, et al.
Publicado: (2022)

The Missing Reality of Real Life in Real‐World Evidence
por: Okun, Sally
Publicado: (2019)

Real world evidence: An Indian perspective
por: Dang, Amit, et al.
Publicado: (2016)

The quality of research with real-world evidence
por: Palacios, Mauricio
Publicado: (2019)

Introduction to real-world evidence studies
por: Chodankar, Deepa
Publicado: (2021)

Automating Access to Real-World Evidence
por: Gauthier, Marie-Pier, et al.
Publicado: (2022)

Real-World Evidence: A Primer
por: Dang, Amit
Publicado: (2023)

The Disruptive Force of Real-World Evidence
por: Schmitt-Egenolf, Marcus
Publicado: (2023)

The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer
por: Raphael, Michael J., et al.
Publicado: (2021)

Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
por: Lin, Pei-Tzu, et al.
Publicado: (2018)

Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence
por: Marchetti, Monia, et al.
Publicado: (2022)

The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications
por: Purpura, Christina A., et al.
Publicado: (2021)

EU-funded initiatives for real world evidence: descriptive analysis of their characteristics and relevance for regulatory decision-making
por: Plueschke, Kelly, et al.
Publicado: (2018)

Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan
por: Hiramatsu, Katsutoshi, et al.
Publicado: (2021)

A narrative review of hydrogen oncology: from real world survey to real world evidence
por: Chen, Ji-Bing, et al.
Publicado: (2020)

The real-world impact of National Institute for Health and Care Excellence's real-world evidence framework
por: Duffield, Stephen, et al.
Publicado: (2023)

Conducting real-world evidence studies in India
por: Bhatt, Arun
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a2fiqb9rslnohc2ov64udpp36g